Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount

Share this

Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount


  • The company will launch Yusimry, a Humira biosimilar with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors) represents an 85% discount from the originator, currently priced at $6,922 per carton of 2 pens
  • Coherus was partnered with the Mark Cuban Cost Plus Drug Company to sell the biosimilar at $569.27 (plus dispensing & shipping fees) and it will be included in the Team Cuban Card prescription benefit program through participating pharmacies
  • Coherus’ patient services platform Yusimry Solutions provide improved access, and a fast & seamless experience as patients start or switch to Yusimry which is a tumor necrosis factor blocker that was approved in the US in 2021 to reduce the signs and symptoms of RA, JIA, PsA, AS, CD, UC, PsO & hidradenitis suppurativa

Ref: Coherus Image: Coherus

Related News:- Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions